TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01582659

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone counseling
Description: 2 planned telephone counseling sessions are conducted.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Web access
Description: Access to a web site with information about childhood constipation similar to the information given at the first visit to the clinic.
Study: NCT02400866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Study: NCT00416689

Intervention type: PROCEDURE
Intervention: assessment of therapy complications

Intervention type: PROCEDURE
Intervention: quality-of-life assessment
Study: NCT05236101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: survey research
Description: Children with dental treatment were asked to draw pictures.
Study: NCT01777568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30% oxygen
Description: Inspired oxygen will be maintained at 30%.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80% oxygen
Description: Inspired oxygen will be maintained at 30%.
Study: NCT00412217

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo tablets (matched to erlotinib) once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be given as 150 mg PO once daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Additional clinical management including surgical resection and chemoradiotherapy or radiotherapy alone will be at the discretion of the Investigator according to local standard of care.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Additional clinical management including surgical resection and chemoradiotherapy or radiotherapy alone will be at the discretion of the Investigator according to local standard of care.
Study: NCT00094536

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extended treatment regimen using Her Option Cryotherapy
Description: Extended treatment regimens using the Her Option Endometrial Cryotherapy System to more effectively ablate the endometrial lining, reducing menstrual levels to normal or less.
Study: NCT02579343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular Acupuncture
Description: Auricular acupuncture is a form of acupuncture which utilizes the surface of the external ear to identify points of inflammation in the body. It does this, in this case, by utilizing the Pointer Excel II probe which can pick up a change in electrical conductivity on the surface of the ear, which reflects an internal point of inflammation or stress. Once the point of inflammation is identified, the Pointer Excel II is equipped with a sensor that it will not only illuminate by way of a small light on the front of the probe will also identify the point of inflammation by way of an auditory signal. Once the point of inflammation is identified auricular acupuncture will treat that point with a micro-current of electricity for several seconds.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Auricular Acupuncture + Lexapro
Description: Participants will be treated with the SSRI Lexapro 10 mg daily which will be increased to 20 mg daily at week 2. Participants will be treated twice weekly during their follow-up visits with sham auricular acupuncture (No micro-current).
Study: NCT02535234

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Novel System
Description: A Novel full Continuous Positive Airway Pressure (CPAP) system - Prototype Device, Mask + Accessories

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Novel System
Description: A Novel full Continuous Positive Airway Pressure (CPAP) system - Prototype Device, Mask + Accessories

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional System
Description: A Traditional full Continuous Positive Airway Pressure (CPAP) system- Released Device + Accessories, Prototype Mask

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional System
Description: A Traditional full Continuous Positive Airway Pressure (CPAP) system- Released Device + Accessories, Prototype Mask
Study: NCT01488669

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot assisted neck dissection via retroauricular approach
Description: A modified face lift or retroauricular incision is made and subplatysmal skin flap is elevated.The marginal mandibular branch of the facial nerve and spinal accessory nerve is identified and lateral part of level II and III is dissected under direct vision using conventional technique. Then, the robotic arms are inserted and the remaining fibrofatty tissue of level I,II,III are dissected under 3D vision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional neck dissection
Description: A transverse skin incision from the mastoid tip to the midline 2 finger below the mandible is made and subplatysmal skin flap is elevated. The fibrofatty tissue of level I,II,III is dissected while preserving the marginal branch of the facial nerve and the spinal accessory nerve. The vessels are ligated using the conventional tie technique and the Harmonic scalpel.
Study: NCT03679338

Intervention type: DEVICE
Group type: OTHER
Intervention: Ablation Therapy
Description: Ablation Therapy With Bipolar Radio frequency
Study: NCT03417024

Intervention type: DEVICE
Intervention: Automated Breast Ultrasound
Description: The ABUS system is designed to methodically scan a breast and capture multiple ultrasound images that can be rendered and reviewed in three dimensions.

Intervention type: DEVICE
Intervention: Digital Breast Tomosynthesis
Description: Digital Breast Tomosynthesis (DBT) systems are designed to collect 3-dimensional x-ray images of breast tissues.
Study: NCT01835275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Audio

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Audio

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audio
Study: NCT00598546

Intervention type: BEHAVIORAL
Intervention: EORTC QLQ-C30, QLQ-STO22, and MSK-10
Description: QLQ-C30 is the generic QOL tool for patients with cancer undergoing clinical trials.QLQ-STO22, containing 22 questions specific to gastric cancer, is currently the only standardized disease-specific questionnaire to measure the QOL of gastric cancer and must be used in conjunction with the QLQ-C30.MSK-10 consists of ten additional questions that were developed by surgeons on the GMT service to answer specific questions about outcomes related to proximal subtotal, distal subtotal, and total gastrectomies. These questions focus on eating capabilities, work status and major life changing events.
Study: NCT02784522

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: locking compression plate group
Description: Closed reduction via shoulder lateral approach followed by locking compression plate fixation using minimally invasive technique

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional locking plate group
Description: Closed reduction via shoulder lateral approach followed by conventional locking plate fixation using minimally invasive technique
Study: NCT02637713

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stretta
Description: Stretta is an FDA approved device that delivers Radiofrequency energy delivery to the lower esophageal sphincter. It is approved for the management of GRED.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) Energy to the LES (Stretta Procedure)
Description: The Stretta procedure is performed endoscopically under moderate sedation or general anesthesia which uses radiofrequency (RF) energy applied to the lower esophagus over 14 minutes per FDA approved procedures.
Study: NCT02195427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEOSYAL® RHA Global Action
Description: A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 30G1/2 disposable sterile needles.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEOSYAL® RHA Deep Lines
Description: A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 27G1/2 disposable sterile needles.
Study: NCT03944369

Intervention type: OTHER
Group type: OTHER
Intervention: KB109
Description: KB109 is a novel glycan

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02530138

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: synbiotic
Description: 2 symbiotics capsules per day for 28 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo capsules per day for 28 weeks
Study: NCT01821443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Description: Dose \& prescription The dose will be prescribed to the isodose surface, which encompasses the margin of the metastasis (50-90% \[maximum=100%\]), as defined by target delineation on the imaging studies.~The prescribed dose is dependent on the prescription isodose volume (IDV). The prescription IDV is defined as the volume (cm3) that is encompassed by the prescription isodose line (IDL).
Study: NCT00664664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD125
Description: soft gelatin capsule, 20 mg, daily dosing for up to 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD125
Description: soft gelatin capsule, 40 mg, daily dosing for up to 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: soft gelatin capsule, daily dosing for up to 3 weeks
Study: NCT04099381

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASD CB-MNC infusion low level HLA compatibility.
Description: CB-MNC infusion from different donors. One dose consists of 2-15х10\^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of the cord blood is 3 or fewer by A, B, DRB1 loci.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASD CB-MNC infusion high level HLA compatibility.
Description: CB-MNC infusion from different donors. One dose consists of 2-15х10\^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of the cord blood is 4 or more by A, B, DRB1 loci.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard therapy.
Description: The standard therapy can include drugs, special psychology training etc.
Study: NCT01777594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-202
Description: G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
Study: NCT00258440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Weekly procrit dosing
Description: The dose is standard of care, the investigational piece is the dosing schedule itself. Either weekly or Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interval Dosing
Description: The dosing of Procrit is standard of care, it is the schedule that is the investigational piece.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interval Dosing
Description: The dosing of Procrit is standard of care, it is the schedule that is the investigational piece.
Study: NCT00005817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: becatecarin
Description: Given IV
Study: NCT03285633

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Mutli-Symptom management(CBT)
Description: Learn to manage distress, fatigue, and/or pain via (Cognitive Behavioral Multi-Symptom management (CBT) four one hour sessions.
Study: NCT03838419

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intraoperative radiotherapy
Description: IORT with 21 Gy prescribed to the 90% isodose line
Study: NCT00005817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: becatecarin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00877149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telbivudine/LDT600
Study: NCT02153658

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subjects cleaned the foreskin with soapy water using a syringe once a day.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subjects cleaned the foreskin with diluted chlorhexidine (1%) using a syringe once a day.
Study: NCT03374670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimura
Description: Zimura in combination with Eylea

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimura
Description: Zimura in combination with Eylea

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eylea
Description: Zimura in combination with Eylea

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eylea
Description: Zimura in combination with Eylea
Study: NCT01905501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balanced anesthesia
Description: Et-Sevo maIntained 1,8-2%, remifentanyl according target-controlled infusion maintained 1-3 ng/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Total intravenous anesthesia
Description: Propofol 3-4 µg/ml and remifentanyl 1-3 ng/ml according target-controlled infusion
Study: NCT01279070

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Repyflec cognitive remediation training
Description: Comparison of 32 Repyflec group sessions among 32 leisure group sessions where we stimulated non-specific cognitive perform.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Repyflec cognitive remediation training
Description: Comparison of 32 Repyflec group sessions among 32 leisure group sessions where we stimulated non-specific cognitive perform.
Study: NCT01200459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social/mobile weight loss promotion intervention.
Description: Social/mobile intervention for weight loss promotion, compared to control group.
Study: NCT02370667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomechanical Exercise (BE)
Description: A biomechanical exercise program shown to decrease joint loading will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Exercise (TE)
Description: A traditional exercise program for people with knee OA will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.

Intervention type: OTHER
Group type: OTHER
Intervention: Meditation Control (M)
Description: A meditation program acting as a control will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
Study: NCT03264378

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise Intervention
Description: The 12-week physical exercise intervention will be delivered by trained community health workers (CHW) who are supervised by nurses. The CHW will visit the patient's home-3 sessions per week for the first 2 weeks, followed by weekly visits for 6 weeks, and then weekly telephone support for 4 weeks-to instruct the family caregiver and the patient in the exercise routine. Each session includes physical activities designed to promote gentle stretching, strength, balance, flexibility, and endurance, with a progressive schedule (i.e., the total length of time increases from 10 minutes up to 30 minutes maximum) and its intensity adjusted based on the participant's level of fitness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise Intervention
Description: The 12-week physical exercise intervention will be delivered by trained community health workers (CHW) who are supervised by nurses. The CHW will visit the patient's home-3 sessions per week for the first 2 weeks, followed by weekly visits for 6 weeks, and then weekly telephone support for 4 weeks-to instruct the family caregiver and the patient in the exercise routine. Each session includes physical activities designed to promote gentle stretching, strength, balance, flexibility, and endurance, with a progressive schedule (i.e., the total length of time increases from 10 minutes up to 30 minutes maximum) and its intensity adjusted based on the participant's level of fitness.
Study: NCT03838419

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: whole breast irradiation
Description: hypofractionated WBI Total dose 40.05 Gy (15 x 2.67 Gy)
Study: NCT02264418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM 203
Description: ODM 203
Study: NCT04323267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Limber Digital Application
Description: A mobile application was recently developed to address these needs. The application provides evidence-based, symptom specific home-exercise video programs for MSK conditions, as well as clinically-validated outcome measures for tracking progress.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy Therapy
Description: Therapy prescription 2 x a week for 8 weeks (specified by physician)
Study: NCT03956615

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling and bone marrow analysis
Description: Bone marrow sample analysis. A blood sampling of maximally 10 ml by venous puncture (serum)
Study: NCT00501059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin (Acetylsalicylic acid, BAYE4465)
Description: 100mg enteric coated Aspirin, taken daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, taken daily
Study: NCT01729520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knee extension strength training
Description: Load experiment: Four knee extensions will be performed with the operated leg at 20, 14, and 8 RM loadings each, in a randomized order. Range of knee joint motion and time under tension for each repetition will be controlled for~Failure experiment: One strength training set of knee extensions will be performed with the operated leg at 10 RM loading until contraction failure. Range of knee joint motion and time under tension for each repetition will be controlled for
Study: NCT01206413

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low glycemic index diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High glycemic index diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-exercisers
Study: NCT02953106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelastine-Fluticasone Nasal
Description: 137 micrograms azelastine hydrochloride / 50 micrograms fluticasone propionate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo nasal spray
Study: NCT02973113

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBVST Cells
Description: EBVST cells in an expected volume of 10-20cc will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3mg/kg (max dose: 240 mg) will be administered as an intravenous infusion over 60 minutes.
Study: NCT02553434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pigtail catheter
Description: Insertion of pigtail catheter
Study: NCT01778699

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: lozenges
Description: The test products for the study is manufactured and provided by CD Investments srl, Italy. The placebo lozenges will look like the active lozenges with the same taste and weight of 1 gram containing only the ingredients listed above in the same proportion as the active but with no L. brevis CD2. It will not be possible to differentiate the two products.~The study center and the monitor must be informed of any deficiency in the study products (products will be kept at 4° degrees during the study).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lozenges
Description: The test products for the study is manufactured and provided by CD Investments srl, Italy. The placebo lozenges will look like the active lozenges with the same taste and weight of 1 gram containing only the ingredients listed above in the same proportion as the active but with no L. brevis CD2. It will not be possible to differentiate the two products.~The study center and the monitor must be informed of any deficiency in the study products (products will be kept at 4° degrees during the study).
Study: NCT03486002

Intervention type: DEVICE
Group type: OTHER
Intervention: Cleansweep
Description: The Cleansweep closed suction system

Intervention type: DEVICE
Group type: OTHER
Intervention: Halyard
Description: Halyard Closed Suction System
Study: NCT02889250

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Activa SC DBS, Lead Model 3387
Description: Deep Brain Stimulation
Study: NCT00077441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies